CD2BP2

CD2 antigen cytoplasmic tail-binding protein 2 · O95400 · CD2BP2 on Sugi Atlas →

0 patent compounds predicted against CD2BP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CD2BP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies PHASE1/PHASE2UNKNOWN
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies PHASE1/PHASE2UNKNOWN
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies PHASE1/PHASE2RECRUITING
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). PHASE1/PHASE2RECRUITING
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies PHASE1/PHASE2UNKNOWN
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors PHASE1/PHASE2RECRUITING
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children PHASE2COMPLETED
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma PHASE1/PHASE2NOT_YET_RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies PHASE1COMPLETED
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies PHASE1UNKNOWN
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. PHASE1UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study nanRECRUITING
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome nanCOMPLETED
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study nanCOMPLETED
Decoy Receptor 3 (DcR3) Polymorphisms in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) nanUNKNOWN
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin nanCOMPLETED
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy nanUNKNOWN
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN nanUNKNOWN
Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD) nanNOT_YET_RECRUITING
Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients nanUNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Markers and Mechanisms of Macrovascular Disease in IDDM nanCOMPLETED
Treatment of Chronic Lymphocytic Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CD2BP2 binder may also engage these)

ProteinNameSimilarity
Q9CWK3 1.000 Q9CWK3 →
Q96K21 0.985 Q96K21 →
Q96I76 0.983 Q96I76 →
Q8VDQ9 0.982 Q8VDQ9 →
Q9D479 0.982 Q9D479 →
Q8BIY1 0.982 Q8BIY1 →
D3ZND0 0.982 D3ZND0 →
Q8N9T8 0.981 Q8N9T8 →
Q8WVB6 0.980 Q8WVB6 →
Q5PPF5 0.980 Q5PPF5 →
Q5R5V9 0.980 Q5R5V9 →
Q99PT3 0.980 Q99PT3 →
Q8VDP4 0.979 Q8VDP4 →
A0JN53 0.979 A0JN53 →
Q5U4Z3 0.979 Q5U4Z3 →
Q66HA5 0.979 Q66HA5 →
F1MX48 0.979 F1MX48 →
Q9C086 0.979 Q9C086 →
Q6P0I6 0.979 Q6P0I6 →
Q0V8M0 0.979 Q0V8M0 →
Q9DBT3 0.979 Q9DBT3 →
Q924T7 0.979 Q924T7 →
Q5T124 0.978 Q5T124 →
Q8BIW9 0.978 Q8BIW9 →
P98175 0.978 P98175 →
Q8K1A6 0.978 Q8K1A6 →
Q66H85 0.978 Q66H85 →
Q3T1I9 0.978 Q3T1I9 →
Q62084 0.978 Q62084 →
Q8VC31 0.978 Q8VC31 →